Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.38 |
| ▸ | CPA2 | P48052 | 1/20 | 0.38 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 4/20 | 0.35 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | GNPAT | O15228 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30632044 | 0.92 | PTPN1 (0.39) | MAGI3MMEKEAP1PTPN1F2 | |
| SCHEMBL30632039 | 0.91 | IL23R (0.40) | MAGI3CPA1CPA2CPA4MME | |
| SCHEMBL19051569 | 0.88 | GNPAT (0.40) | CPA1CPA2CPA4MMEBACE1 | |
| SCHEMBL30632042 | 0.88 | BACE1 (0.40) | MAGI3BACE1PTPN1IL23RBACE2 | |
| SCHEMBL21766761 | 0.87 | BACE1 (0.41) | MAGI3BACE1PTPN1BACE2 | |
| SCHEMBL21766737 | 0.86 | MAGI3 (0.39) | MAGI3KEAP1BACE1PTPN1BACE2 | |
| SCHEMBL30632040 | 0.85 | FURIN (0.40) | BACE1 | |
| SCHEMBL31094977 | 0.83 | PTPN1 (0.46) | KEAP1BACE1PTPN1F2BACE2 | |
| SCHEMBL31746072 | 0.83 | PTPN1 (0.49) | BACE1PTPN1BACE2 | |
| SCHEMBL29530913 | 0.83 | MME (0.40) | MAGI3MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771774-B2 | Nerve labeling compositions and uses thereof | AVELAS ACQUISITION CORPORATION (US) | 2023-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771774-B2 | Nerve labeling compositions and uses thereof | GAP43, NGF, PMP22 | MAGI3 2150/4885CPA1 3343/4885CPA2 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.